# A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

> **NCT01021358** · PHASE1 · COMPLETED · sponsor: **Abbott** · enrollment: 12 (estimated)

## Conditions studied

- Lymphoma
- Chronic Lymphocytic Leukemia
- Solid Tumors

## Interventions

- **DRUG:** ABT-263
- **DRUG:** Ketoconazole

## Key facts

- **NCT ID:** NCT01021358
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2010-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021358, "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01021358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*